Silverback Therapeutics, Inc.

Juno Therapeutics Gmbh

Araris Biotech Ag

Valerie Odegard

Peter Robert Baum

Robert Dubose

Brenda L Stevens

Philip Tan

Jeff D Smith

Mark J Gilbert

He Li

Christopher Glen Ramsborg

Ryan P Larson

Sean Wesley Smith

Pascal Beauchesne

Tom Kowski

Clinton Weber

Nathan K Yee

Kathryn Lindsay Pollock

Brian Christin

Claire L Sutherland

Kedar Himanshu Dave

Mary Mallaney

Andrew W Walker

Brenda Stevens

Nikolaus Sebastian Trede

Michael Gerard Covington

Richard James Getto, Jr

James Boyd Whitmore

Travis Beckett

Samuel Charles Blackman

Nathaniel Chartrand

Peter A Thompson

Nathaniel Lambert

Mel Davis-pickett

The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.

Nectin-4 antibody conjugates and uses thereof

Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.

Determining toxicity risk in CAR T-cell therapy

The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.

Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof

Growing community of inventors

Seattle, WA, United States of America

Valerie Odegard